Iron Deficiency Anemia - Pipeline Review, H2 2018

Publisher Name :
Date: 17-Jul-2018
No. of pages: 79
Inquire Before Buying

Iron Deficiency Anemia - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2018, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 3, 3, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Iron Deficiency Anemia - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Iron Deficiency Anemia - Overview
Iron Deficiency Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Iron Deficiency Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iron Deficiency Anemia - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
Galenica Ltd
Novartis AG
Panion & Bf Biotech Inc
Pharmacosmos AS
Pieris Pharmaceuticals Inc
Rockwell Medical Inc
Shield Therapeutics Plc
Iron Deficiency Anemia - Drug Profiles
AKB-5343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSJ-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric maltol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric pyrophosphate citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hinokitiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iron isomaltoside - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-8679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polyglucoferron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-30 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Iron Deficiency Anemia - Dormant Projects
Iron Deficiency Anemia - Product Development Milestones
Featured News & Press Releases
Jun 28, 2018: Shield Reports Recently Presented Supportive Data from Real-world Clinical use of Feraccru (Ferric Maltol)
Jun 14, 2018: Shield reports positive top-line results from its AEGIS-PAED PK Pediatric Phase I Pharmacokinetics study of Feraccru (Ferric Maltol) in subjects with iron deficiency
May 02, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 International Congress on Peritoneal Dialysis
Apr 06, 2018: Shield Therapeutics Announces Results of its Pre-Submission Meeting with FDA
Mar 27, 2018: Shield receives EU Commission approval for the broadening of the indication for Feraccru (Ferric Maltol) to the treatment of Iron Deficiency in adults
Mar 20, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 Asia Pacific Congress of Nephrology
Mar 16, 2018: Shield Therapeutics: Update on the AEGIS-CKD study
Feb 28, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 Annual Dialysis Conference
Feb 28, 2018: Iron4u Completed Clinical Phase II and Granted PIP by EMA for New Human IV Iron
Feb 23, 2018: Shield Therapeutics receives CHMP positive opinion for Feraccru (Ferric Maltol) for the treatment of Iron Deficiency in adults
Feb 22, 2018: Shield Therapeutics Provides Update on Feraccru
Feb 05, 2018: Shield reports top-line results from pivotal Phase III study of Feraccru (Ferric Maltol) in the treatment of IDA in patients with CKD
Nov 07, 2017: U.S. FDA Approves Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
Nov 02, 2017: Keryx Biopharmaceuticals Announces Presentation of Post-Hoc Data From Phase 3 Study of Auryxia (Ferric Citrate) in Adults With Iron Deficiency Anemia and Non-dialysis Dependent Chronic Kidney Disease
Oct 30, 2017: Rockwell Medical Announces Two Triferic Poster Presentations at American Society of Nephrology Kidney Week 2017 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Iron Deficiency Anemia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Iron Deficiency Anemia - Pipeline by Akebia Therapeutics Inc, H2 2018
Iron Deficiency Anemia - Pipeline by Galenica Ltd, H2 2018
Iron Deficiency Anemia - Pipeline by Novartis AG, H2 2018
Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H2 2018
Iron Deficiency Anemia - Pipeline by Pharmacosmos AS, H2 2018
Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals Inc, H2 2018
Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, H2 2018
Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, H2 2018
Iron Deficiency Anemia - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Iron Deficiency Anemia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • 2018-2023 Global Hydroxycarbamide Consumption Market Report
    Published: 20-Aug-2018        Price: US 4660 Onwards        Pages: 163
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Hydroxycarbamide market for 2018-2023. Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth. Common side effects include bone marrow suppression, fevers, loss of app......
  • Global and India Cytotoxic Drug Market Research by Company, Type & Application 2013-2025
    Published: 19-Aug-2018        Price: US 2000 Onwards        Pages: 86
    Summary Cytotoxic drugs inhibit or prevent the function of cells. Cytotoxic drugs are primarily used to treat cancer, frequently as part of a chemotherapy regime. Recently, their uses have expanded to treat certain skin conditions (e.g., psoriasis), rheumatoid and juvenile rheumatoid arthritis, and steroid-resistant muscle conditions. The most common forms of cytotoxic drugs are known as antineoplastic. The terms ‘antineoplastic' and ‘cytotoxic' are often used interchangeably.......
  • Global and India Lentinan Market Research by Company, Type & Application 2013-2025
    Published: 18-Aug-2018        Price: US 2000 Onwards        Pages: 114
    Summary Lentinan is a beta-glucan (a type of polysaccharide) from the mushroom lentinus edodes (shiitake mushroom). It has been studied in Japan as a treatment for cancer. Market Segment as follows: By Type - Food Grade - Pharmaceutical Grade - Others By Application - Food additive - Health product field - Anti-cancer drug - Others By Company - Ajinomoto - Elicityl......
  • Global Erlotinib Hydrochloride Market Insights, Forecast to 2025
    Published: 15-Aug-2018        Price: US 3900 Onwards        Pages: 99
    This report studies the global market size of Erlotinib Hydrochloride in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Erlotinib Hydrochloride in these regions. This research report categorizes the global Erlotinib Hydrochloride market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, mark......
  • Global and India Cancer Treatment Drugs Market Research by Company, Type & Application 2013-2025
    Published: 15-Aug-2018        Price: US 2000 Onwards        Pages: 120
    Summary Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others. Market Segment as follows: By Type - Chemotherapy - Targeted Therapy - Immunotherapy (Biologic Therapy) - Hormonal Therapy - Others By Application - Blood Cancer - Breast Cancer - ......
  • Global Capecitabine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 14-Aug-2018        Price: US 3480 Onwards        Pages: 134
    Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Scope of the Report: This report focuses on the Capecitabine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Capecitabine Market 2018, Forecast to 2023
    Published: 14-Aug-2018        Price: US 4880 Onwards        Pages: 135
    Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Scope of the Report: This report focuses on the Capecitabine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This......
  • Global and India Capecitabine Market Research by Company, Type & Application 2013-2025
    Published: 13-Aug-2018        Price: US 2000 Onwards        Pages: 99
    Summary Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Market Segment as follows: By Type - 500 mg - 150 mg By Application - Breast Cancer - Colorectal cancer - Stomach Cancer ......
  • Global and India Mitomycin C Market Research by Company, Type & Application 2013-2025
    Published: 13-Aug-2018        Price: US 2000 Onwards        Pages: 102
    Summary Mitomycin C is an antibiotic which acts as a double-stranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NAD(P)H:quinone oxidoreductase (DT-diaphorase) or NADH cytochrome c reductase (Mao et al.; Cummings et al.). Market Segment as follows: By Type - 2 Mg - 10 Mg - 40 Mg - Others By Application - Cancer Trea......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs